Abenacianine for injection (VGT-309)

About Vergent Bioscience

Vergent Bioscience is a private, clinical-stage biotech developing VGT-309, a targeted fluorescent imaging agent that illuminates tumors during surgery by binding to cathepsin proteases. The company is currently running a Phase 2b study in lung cancer to help surgeons remove all tumor tissue, particularly in minimally invasive and robotic-assisted procedures. By addressing a critical unmet need in surgical oncology, Vergent aims to improve surgical outcomes and establish itself as a leader in intraoperative tumor visualization. The technology platform has the potential for application across multiple solid tumor types.

Therapeutic Areas